Komori
Human Metabolome Technologies (6090) · PolicyRaised

Policy of prioritizing retained earnings and considering future dividends

First written in FY2017. 6 of 13 entries say "Raised", first in FY2024. Latest entry: FY2026.

13entries
10years
5from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2017 – FY2020AchievedFY2023 – FY20242017: 120172018: 020182019: 120192020: 120202021: 020212022: 020222023: 220232024: 120242025: 120252026: 62026
Same theme, other companies
Policy of prioritizing retained earnings while considering stable dividends in the futureA theme 49 companies write about · 14 as a headwind · 17 as a tailwind

The whole theme swung hardest in 2017: 1 of 12 companies on the "Worse" side.

6 other companies' latest entry also says "Raised".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 49 companies compared. The sentences above are computed from all 49.
Full recordFilings, disclosures and news, newest first
  1. FY2026RaisedAnnual report

    「We decided to retain a certain amount of retained earnings as working capital and strategic investment funds, including M&A and capital expenditures, and to allocate any excess to shareholder returns. For the fiscal year ending June 2026, we resolved to pay a year-end dividend of ¥18.00 per share in accordance with our policy of maintaining a payout ratio of at least 40%.」

    The company changed from its previous policy of prioritizing retained earnings to allocating the surplus remaining after securing working capital and strategic investment funds to shareholder returns, and indicated a payout ratio of at least 40% and a dividend of ¥18 per share.
  2. FY2025-H1RestatedAnnual report

    「This was attributable to the recording of interim net income attributable to owners of the parent of ¥93.218 million, while dividend payments amounted to ¥88.733 million and stock acquisition rights decreased by ¥25.083 million due to their maturity and redemption, among other factors.」

    Dividends were paid in accordance with the profit distribution policy, with dividend payments of ¥88.733 million made during the interim consolidated accounting period.
  3. FY2024RaisedAnnual report

    「For the fiscal year ended June 2024, the company resolved to pay a year-end dividend of ¥15.00 per share in accordance with its policy of maintaining a payout ratio of at least 30%.」

    The company increased the dividend from the previous year’s initial dividend of ¥10 per share to ¥15 per share and stated a policy of maintaining a payout ratio of at least 30%.
  4. FY2024-Q1AchievedAnnual report

    「At a meeting of the Board of Directors held on 10 August 2023, the company resolved to pay a year-end dividend as follows.」

    The company paid a year-end dividend for the fiscal year ended June 2023 totaling ¥59.07 million, or ¥10 per share, on 7 September 2023.
  5. FY2023AchievedAnnual report

    「As consolidated results for the year-end showed that retained earnings had reached a certain level, the company resolved to pay an initial dividend to return profits to shareholders while securing capacity for growth investment and pursuing shareholder returns. It resolved to pay a year-end dividend of ¥10.00 per share for the fiscal year ended June 2023.」

    The company progressed from its previous policy of prioritizing retained earnings and considering future dividends to paying its first dividend for the fiscal year ended June 2023. The payout ratio was 21.7%.
  6. FY2020RestatedAnnual report

    「At the end of the 17th fiscal year, retained earnings brought forward were still negative, and the company’s policy was to prioritize strengthening retained earnings to secure the funds required for biomarker development, overseas expansion and other purposes.」

    Because retained earnings brought forward are negative, the company continues to prioritize retained earnings while considering future dividends.
  7. FY2019RestatedAnnual report

    「We will prioritize strengthening retained earnings to secure the funds required for biomarker development, overseas expansion and other purposes. However, we recognize the return of profits to shareholders as an important management issue, and will consider paying dividends in light of future operating results and financial position.」

    The company has reaffirmed its policy of prioritizing retained earnings while considering future dividends.
  8. FY2017First statedAnnual report

    「We will prioritize strengthening retained earnings to secure the funds required for biomarker development, overseas expansion and other purposes. However, we recognize the return of profits to shareholders as an important management issue, and will consider paying dividends in light of future operating results and financial position.」

    Because retained earnings brought forward are negative, the company has indicated a policy of prioritizing retained earnings while considering future dividend payments.
Moved together

"Productivity Improvement in Analytical Work" moved the same way as this thread, in the same document, in 5 of its 13 moves.

555444★123456
  1. ★This thread
  2. 1Productivity Improvement in Analytical Work5×
  3. 2Capital investment to expand analytical capabilities and accelerate research and development5×
  4. 3Healthcare Solutions Business: ¥100 million in sales and segment profitability in five years5×
  5. 4Development of New Markets Related to Foods with Function Claims and Other Areas4×
  6. 5Development of a New Service in the Metabolome Analysis Business4×
  7. 6Launch of a Comprehensive Support Service for Functional Materials Development and Establishment of a Business Foundation4×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Human Metabolome Technologies yet. It last moved in the General Meetings of Shareholders of 2026-08-25: "Raised".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Policy of prioritizing retained earnings and considering future dividends | Human Metabolome Technologies,Inc. (6090) | Komori